Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 3Severe Combined Immunodeficiency 1Rectal Neoplasms 1Neuroblastoma 1Mucopolysaccharidosis I 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 180Capecitabine 174Fluorouracil 154Radiotherapy 107Leucovorin 107Irinotecan 93Bevacizumab 69Surgical Procedures, Operative 49Cetuximab 39Drug Therapy 38Radiation 35Neoadjuvant Therapy 33Folfox protocol 29Chemoradiotherapy 29XELOX 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 21Radiotherapy, Intensity-Modulated 19Surveys and Questionnaires 17Proctectomy 16Biopsy 16Early Intervention, Educational 14trifluridine tipiracil drug combination 12Panitumumab 12Floxuridine 12tislelizumab 11regorafenib 11Nivolumab 11Laparoscopy 11Celecoxib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rectal Neoplasms × Biological Specimen Banks × Clear all
NCT01850654 2018-06-28

OCCPI

Ohio State University Comprehensive Cancer Center

Phase NA Completed
3,470 enrolled
GastrointestinalGynecologic

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡